Brief: Cytomx And Regeneron Announce Strategic Research Collaboration In The Field Of Conditional Bispecific Therapeutics For The Treatment Of Cancer
17/11/2022 12:44
Nov 17 (Reuters) - CytomX Therapeutics Inc CTMX.O :
* CYTOMX AND REGENERON ANNOUNCE STRATEGIC RESEARCH
COLLABORATION
IN THE FIELD OF CONDITIONAL BISPECIFIC THERAPEUTICS FOR THE
TREATMENT OF CANCER
* REGENERON - CYTOMX TO RECEIVE $30 MILLION UPFRONT PAYMENT
WITH
POTENTIAL FOR UP TO $2 BILLION IN RESEARCH, DEVELOPMENT,
REGULATORY AND SALES-BASED MILESTONES
* REGENERON PHARMACEUTICALS INC - CYTOMX IS ALSO ELIGIBLE TO
RECEIVE TIERED GLOBAL NET SALES ROYALTIES
Source text for Eikon: ID:nGNX3sBTQy
Further company coverage: CTMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway